Lesko LJ - Search Results

1

Medical applications of microarray technologies: a regulatory science perspective.

Petricoin EF 3rd, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, Woodcock J, Feigal DW Jr, Zoon KC, Sistare FD. Petricoin EF 3rd, et al. Among authors: lesko lj. Nat Genet. 2002 Dec;32 Suppl:474-9. doi: 10.1038/ng1029. Nat Genet. 2002. PMID: 12454641 Review.

2

Microarray data--the US FDA, industry and academia.

Hackett JL, Lesko LJ. Hackett JL, et al. Among authors: lesko lj. Nat Biotechnol. 2003 Jul;21(7):742-3. doi: 10.1038/nbt0703-742. Nat Biotechnol. 2003. PMID: 12833089 No abstract available.

3

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective.

Lesko LJ, Woodcock J. Lesko LJ, et al. Nat Rev Drug Discov. 2004 Sep;3(9):763-9. doi: 10.1038/nrd1499. Nat Rev Drug Discov. 2004. PMID: 15340386 Review.

4

Pharmacological mechanism-based drug safety assessment and prediction.

Abernethy DR, Woodcock J, Lesko LJ. Abernethy DR, et al. Among authors: lesko lj. Clin Pharmacol Ther. 2011 Jun;89(6):793-7. doi: 10.1038/clpt.2011.55. Epub 2011 Apr 13. Clin Pharmacol Ther. 2011. PMID: 21490594 Review.

5

Pharmacogenomic-guided drug development: regulatory perspective.

Lesko LJ, Woodcock J. Lesko LJ, et al. Pharmacogenomics J. 2002;2(1):20-4. doi: 10.1038/sj.tpj.6500046. Pharmacogenomics J. 2002. PMID: 11990376 No abstract available.

6

Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop.

Lesko LJ, Salerno RA, Spear BB, Anderson DC, Anderson T, Brazell C, Collins J, Dorner A, Essayan D, Gomez-Mancilla B, Hackett J, Huang SM, Ide S, Killinger J, Leighton J, Mansfield E, Meyer R, Ryan SG, Schmith V, Shaw P, Sistare F, Watson M, Worobec A. Lesko LJ, et al. J Clin Pharmacol. 2003 Apr;43(4):342-58. doi: 10.1177/0091270003252244. J Clin Pharmacol. 2003. PMID: 12723455

7

Pharmacogenetics--tailoring treatment for the outliers.

Woodcock J, Lesko LJ. Woodcock J, et al. Among authors: lesko lj. N Engl J Med. 2009 Feb 19;360(8):811-3. doi: 10.1056/NEJMe0810630. N Engl J Med. 2009. PMID: 19228625 No abstract available.

8

Population pharmacokinetics. A regulatory perspective.

Sun H, Fadiran EO, Jones CD, Lesko L, Huang SM, Higgins K, Hu C, Machado S, Maldonado S, Williams R, Hossain M, Ette EI. Sun H, et al. Clin Pharmacokinet. 1999 Jul;37(1):41-58. doi: 10.2165/00003088-199937010-00003. Clin Pharmacokinet. 1999. PMID: 10451782 Review.

9

Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report.

Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, Peck CC. Galluppi GR, et al. Among authors: lesko lj. Clin Pharmacol Ther. 2001 Jun;69(6):387-99. doi: 10.1067/mcp.2001.115455. Clin Pharmacol Ther. 2001. PMID: 11406736 No abstract available.

10

Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.

Wang Y, Bhattaram AV, Jadhav PR, Lesko LJ, Madabushi R, Powell JR, Qiu W, Sun H, Yim DS, Zheng JJ, Gobburu JV. Wang Y, et al. Among authors: lesko lj. J Clin Pharmacol. 2008 Feb;48(2):146-56. doi: 10.1177/0091270007311111. J Clin Pharmacol. 2008. PMID: 18199891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

217 results

Search Page